• Latest
  • Trending
Mubadala Capital announces $200 million in Tenvie Therapeutics for Alzheimer’s, Parkinson’s disease therapies

Mubadala Capital announces $200 million in Tenvie Therapeutics for Alzheimer’s, Parkinson’s disease therapies

January 13, 2025
Innoson, Nigerian automaker, unveils plan to establish CNG assembly plant

Innoson, Nigerian automaker, unveils plan to establish CNG assembly plant

October 16, 2025
Spotify testing ‘SongDNA’ to show everyone behind your songs

Spotify testing ‘SongDNA’ to show everyone behind your songs

October 16, 2025
$395mn submarine cable project, Medusa, begins deployment to link Europe to Africa

$395mn submarine cable project, Medusa, begins deployment to link Europe to Africa

October 16, 2025
Chari raises $12M, gets Morocco’s first VC-backed payment license

Chari raises $12M, gets Morocco’s first VC-backed payment license

October 16, 2025
NCBA unveils ConnectPlus to improve businesses in Kenya

NCBA unveils ConnectPlus to improve businesses in Kenya

October 16, 2025
Slack supercharges Slackbot with smarter AI capabilities

Slack supercharges Slackbot with smarter AI capabilities

October 16, 2025
Gemini AI now handles your Google Calendar meeting scheduling

Gemini AI now handles your Google Calendar meeting scheduling

October 16, 2025
Sun King, REA partner to boost access to clean energy

Sun King, REA partner to boost access to clean energy

October 16, 2025
ChatGPT to allow erotica for adult users, Sam Altman says

ChatGPT to allow erotica for adult users, Sam Altman says

October 16, 2025
UNILAG partners with OpenAI to bring first African academy to Lagos

UNILAG partners with OpenAI to bring first African academy to Lagos

October 16, 2025
How Nigerian innovators are transforming lecture notes for the digital age

How Nigerian innovators are transforming lecture notes for the digital age

October 16, 2025
PayTabs, Valu launch contactless payment system for Egyptian merchants

PayTabs, Valu launch contactless payment system for Egyptian merchants

October 15, 2025
Techpression
Advertisement
  • Tech News
    • Africa Tech
    • Global Tech
    • Tech with Pelumy
    • Tech Careers
    • Tech TV
    • General News
    • How To
    • Reviews
  • Cryptocurrency
  • Fintech
  • Startups
  • Ai
Friday, October 17, 2025
No Result
View All Result
  • Tech News
    • Africa Tech
    • Global Tech
    • Tech with Pelumy
    • Tech Careers
    • Tech TV
    • General News
    • How To
    • Reviews
  • Cryptocurrency
  • Fintech
  • Startups
  • Ai
No Result
View All Result
Techpression
No Result
View All Result
Home Business Editors Pick

Mubadala Capital announces $200 million in Tenvie Therapeutics for Alzheimer’s, Parkinson’s disease therapies

Modupeoluwa Olalere by Modupeoluwa Olalere
January 13, 2025
in Editors Pick
143 9
0
Mubadala Capital announces $200 million in Tenvie Therapeutics for Alzheimer’s, Parkinson’s disease therapies

Mubadala Capital announces $200 million in Tenvie Therapeutics for Alzheimer’s, Parkinson’s disease therapies

472
SHARES
Share on FacebookShare on TwitterWhatsAppTelegram

Mubadala Capital has recently announced a significant investment of $200 million in Tenvie Therapeutics on January 9, 2025. 

Tenvie, which Tony Estrada started, is focused on developing new treatments for diseases that affect the brain and nervous system, which can profoundly impact people’s lives.

Read also: HealthTech Hub Africa launches 2025 program for African health startups

A new hope for patients

Tony Estrada, the founder and chief scientist of Tenvie, expressed his vision by saying, “Tenvie was founded to fundamentally alter the treatment paradigm for neurological diseases and profoundly impact the lives of patients, their families, and caregivers.” 

RelatedPosts

No Content Available
Load More

This means that Tenvie aims to change how we approach the treatment of these complex illnesses, making it possible to improve the quality of life for those affected. 

The company is working on innovative therapies that target inflammation and restore brain function, which could lead to better outcomes for patients suffering from conditions like Alzheimer’s disease and Parkinson’s disease.

Support from Mubadala Capital

Mubadala Capital’s investment highlights its commitment to supporting groundbreaking healthcare innovations. Alaa Halawa, who leads Mubadala’s healthcare investments, remarked, “Tenvie’s approach demonstrates a commitment to addressing unmet needs in neurology.”

This funding will enable Tenvie to expand its research and development efforts significantly. With a strong lineup of potential treatments already in the pipeline, Tenvie is well-positioned to make a meaningful difference in biotechnology and help many individuals struggling with neurological disorders. 

Read also: Compass Global’s initiative bridges Africa’s trade gaps, focuses on youth and women entrepreneurs

About Tenvie Therapeutics

Tenvie Therapeutics is a biotechnology company founded to improve patients’ lives with neurological, cardiometabolic, and ophthalmic diseases.

The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics.

Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

Tags: Mubadala CapitalTenvie Therapeutics
Modupeoluwa Olalere

Modupeoluwa Olalere

Modupe is a tech content writer with 3+ years of experience turning complex ideas into clear, engaging stories. She covers innovation, digital trends, and emerging technologies. When she’s not writing, she’s exploring new tools or tracking trends shaping Africa’s tech ecosystem.

Quick Links

  • Tech News
  • Cryptocurrency
  • Fintech
  • Startups
  • Business
  • Home
  • About
  • Contact Us
  • Advert Rate
  • Terms & Conditions
  • Privacy Policy
  • SiteMap

© 2025 Techpression

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

No Result
View All Result
  • Home
  • Tech News
    • Africa Tech
    • Global Tech
    • Tech with Pelumy
    • Tech Careers
    • Reviews
    • How To
    • General News
  • Cryptocurrency
  • Business
  • Fintech
  • Startups
  • Featured
  • Ai
  • Tech TV

© 2025 Techpression

techpression.com
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.